Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Amylyx Pharmaceuticals Inc

AMLX ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Mid Cap Analyst: BUY

Last Close

$21.63

▼ -3.78%

Market Cap $2.41B · Vol 610.77K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$2.41B

Mid Cap

Div Yield

N/A

EPS Growth

+3.86%

YoY

RSI (14)

60.31

Momentum

Beta

-0.20

vs Market

52W High

$24.59

12.02% below

52W Low

$7.63

183.49% above

Volume

610.77K

Avg 543.31K

P/B

4.35

Price-to-book

ROE

-61.59%

Return on equity

Free Float

84.69%

Public shares

Shariah Compliance8 STANDARDS

✗ Amylyx Pharmaceuticals Inc (AMLX) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does AMLX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-5.21%

+18.85%

+55.84%

+53.19%

YTD

+79.06%

+157.19%

+3.00%

N/A

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-144,735,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	-61.59%
ROA · ROIC	-54.99% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	4.35
P/FCF	N/A
EPS Growth	+3.86%
Outstanding Shares	111.42M

Technical Indicators

50-Day SMA	$18.15
200-Day SMA	$15.22
RSI (14)	60.31
Beta	-0.20
52-Week High	$24.59
52-Week Low	$7.63

Volume Today	610.77K
Avg Daily Volume (30D)	543.31K
Relative Volume	1.12x
Volatility (10D)	78.71
Volatility (30D)	62.92
Free Float	84.69%

Analyst Consensus

BUY

Current Price $21.63

Mean Target $27.50

52W Low$7.63 52W High$24.59

Current

Target

$7.63 $24.59

Current Analyst target

+27.14% upside potential · 9 analysts

Identifiers

ExchangeNasdaq

FIGIBBG00DP10YW1

ISINUS03237H1014

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 4, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

Amylyx Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on four investigational therapies across several diseases. Its lead investigational asset is avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist. Avexitide has been evaluated as a treatment for Post-Bariatric Hypoglycemia (PBH) and congenital HI, two indications characterized by hyperinsulinemic hypoglycemia. In addition to avexitide, it is advancing AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol in Wolfram syndrome, AMX0114 in amyotrophic lateral sclerosis (ALS), and AMX0318 in PBH and other rare diseases. AMX0035 is designed to mitigate neurodegeneration by targeting endoplasmic reticulum stress and mitochondrial dysfunction, two cellular processes central to neuronal cell death and neurodegeneration. AMX0114 is an investigational antisense oligonucleotide and AMX0318 is a novel GLP-1 receptor antagonist.